Aimmune Therapeutics, Inc. Information Request Form

Levi & Korsinsky, LLP has commenced an investigation into the fairness of the sale of Aimmune Therapeutics, Inc. (“Aimmune” or the “Company”) (NASDAQ: AIMT) to Nestlé S.A. Under the terms of the merger agreement, Nestlé S.A.’s wholly-owned subsidiary, Société des Produits Nestlé S.A., will commence a cash tender offer to acquire all outstanding shares of Aimmune common stock that are not already owned by Nestlé Health Science for $34.50 per share in cash.

The Aimmune merger investigation concerns whether the Board of Aimmune has harmed stockholders by agreeing to enter into this transaction and whether all material facts have been properly disclosed to stockholders.